Crossmark

Dose predictions for [177Lu]Lu-DOTA-panitumumab F(ab′)2 in NRG mice with HNSCC patient-derived tumour xenografts based on [64Cu]Cu-DOTA-panitumumab F(ab′)2 – implications for a PET theranostic strategy

Crossref DOI link: https://doi.org/10.1186/s41181-021-00140-1

Published Online: 2021-08-12

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ku, Anthony

Kondo, Misaki

Cai, Zhongli

Meens, Jalna

Li, Min Rong

Ailles, Laurie

Reilly, Raymond M.
Funding

Funding for this research was provided by:

Canadian Cancer Society (Innovation-to-Impact Grant)

Government of Ontario (QEII-GSST Scholarship)

University of Toronto (CPO Scholarship, CPO Scholarship, Second Reuben Wells Fellowship, University College Alumni Scholarship)

Terry Fox Foundation (STARS21 Scholarship)

amgen canada (Materials Transfer Agreement)
License Information

Text and Data Mining valid from 2021-08-12

Version of Record valid from 2021-08-12
More Information

Article History

Received: 16 March 2021

Accepted: 6 July 2021

First Online: 12 August 2021

Declarations

:

: This study was carried out in accordance with Canadian Council on Animal Care (CCAC) guidelines. The protocol (AUP 2843.8) was approved by the institutional Animal Care Committee of the University Health Network.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below